- Have Stage III, Stage IV, or recurrent, histologically-confirmed endometrial carcinoma with disease that is either measurable or non-measurable per RECIST 1.1 but radiographically apparent, as assessed by BICR.
- May have received prior chemotherapy only if administered concurrently with radiation
- May have received prior radiation
- May have received prior hormonal therapy for treatment of endometrial carcinoma, provided that it was discontinued ≥1 week prior to randomization
Please contact Legacy Oncology Research for additional study inclusion/exclusion information.